Michael D Huband1, Michael A Pfaller2, Dee Shortridge3, Robert K Flamm3. 1. JMI Laboratories, North Liberty, IA, USA. Electronic address: michael-huband@jmilabs.com. 2. JMI Laboratories, North Liberty, IA, USA; University of Iowa, Iowa City, IA, USA. 3. JMI Laboratories, North Liberty, IA, USA.
Abstract
OBJECTIVES: Omadacycline is an aminomethylcycline antibacterial (oral and intravenous once-daily formulation) that recently (October 2018) received United States Food and Drug Administration (FDA) approval for the treatment of acute bacterial skin and skin structure infections (ABSSSIs) and community-acquired bacterial pneumonia (CABP) against selected organism groups. This study tested omadacycline and comparators against 14 000 non-duplicate bacterial isolates that were prospectively collected during 2017 from medical centres in Europe (EUR; 7000 isolates) and the United States (USA; 7000 isolates). METHODS: Omadacycline was tested by broth microdilution following Clinical and Laboratory Standards Institute M07-A11 (2018) methods. RESULTS: A total of 98.7% ofStaphylococcus aureus isolates were susceptible to omadacycline (MIC50/90, 0.12/0.25mg/L; ABSSSI breakpoints) including 96.5% of methicillin-resistant Staphylococcus aureus (MRSA), 99.8% of methicillin-susceptible Staphylococcus aureus, and 93.9% of tetracycline-resistant strains. Omadacycline activity was similar for Streptococcus pneumoniae (MIC50/90 0.06/0.12mg/L; 98.6% susceptible [CABP breakpoints]), Streptococcus anginosus group (MIC50/90 0.06/0.06mg/L; 100.0% susceptible [ABSSSI breakpoints]), and Streptococcus pyogenes (MIC50/90 0.06/0.12mg/L; 97.7% susceptible [ABSSSI breakpoints]). Omadacycline demonstrated activity against Enterobacter cloacae species complex isolates (MIC50/90, 2/4mg/L; 91.2% susceptible [ABSSSI breakpoints]), Klebsiella pneumoniae (MIC50/90, 2/8mg/L; 87.5% susceptible [CABP and ABSSSI breakpoints]), and inhibited 99.1% of Escherichia coli (MIC50/90, 0.5/2mg/L) isolates at ≤ 4mg/L. Omadacycline was active against Haemophilus influenzae (MIC50/90, 0.5/1mg/L; 99.8% susceptible [CABP breakpoints]), including all β-lactamase positive isolates, and inhibited 100.0% of Moraxella catarrhalis isolates at ≤ 0.25mg/L. CONCLUSIONS: The potent activity of omadacycline against Gram-positive and Gram-negative bacteria indicates that omadacycline merits further study in serious infections in which multidrug resistance and mixed Gram-positive and Gram-negative infections may be of concern.
OBJECTIVES:Omadacycline is an aminomethylcycline antibacterial (oral and intravenous once-daily formulation) that recently (October 2018) received United States Food and Drug Administration (FDA) approval for the treatment of acute bacterial skin and skin structure infections (ABSSSIs) and community-acquired bacterial pneumonia (CABP) against selected organism groups. This study tested omadacycline and comparators against 14 000 non-duplicate bacterial isolates that were prospectively collected during 2017 from medical centres in Europe (EUR; 7000 isolates) and the United States (USA; 7000 isolates). METHODS:Omadacycline was tested by broth microdilution following Clinical and Laboratory Standards Institute M07-A11 (2018) methods. RESULTS: A total of 98.7% ofStaphylococcus aureus isolates were susceptible to omadacycline (MIC50/90, 0.12/0.25mg/L; ABSSSI breakpoints) including 96.5% of methicillin-resistant Staphylococcus aureus (MRSA), 99.8% of methicillin-susceptible Staphylococcus aureus, and 93.9% of tetracycline-resistant strains. Omadacycline activity was similar for Streptococcus pneumoniae (MIC50/90 0.06/0.12mg/L; 98.6% susceptible [CABP breakpoints]), Streptococcus anginosus group (MIC50/90 0.06/0.06mg/L; 100.0% susceptible [ABSSSI breakpoints]), and Streptococcus pyogenes (MIC50/90 0.06/0.12mg/L; 97.7% susceptible [ABSSSI breakpoints]). Omadacycline demonstrated activity against Enterobacter cloacae species complex isolates (MIC50/90, 2/4mg/L; 91.2% susceptible [ABSSSI breakpoints]), Klebsiella pneumoniae (MIC50/90, 2/8mg/L; 87.5% susceptible [CABP and ABSSSI breakpoints]), and inhibited 99.1% of Escherichia coli (MIC50/90, 0.5/2mg/L) isolates at ≤ 4mg/L. Omadacycline was active against Haemophilus influenzae (MIC50/90, 0.5/1mg/L; 99.8% susceptible [CABP breakpoints]), including all β-lactamase positive isolates, and inhibited 100.0% of Moraxella catarrhalis isolates at ≤ 0.25mg/L. CONCLUSIONS: The potent activity of omadacycline against Gram-positive and Gram-negative bacteria indicates that omadacycline merits further study in serious infections in which multidrug resistance and mixed Gram-positive and Gram-negative infections may be of concern.
Authors: Michael A Pfaller; Michael D Huband; Dee Shortridge; Robert K Flamm Journal: Antimicrob Agents Chemother Date: 2020-04-21 Impact factor: 5.191
Authors: Michael D Huband; Rodrigo E Mendes; Michael A Pfaller; Jill M Lindley; Gregory J Strand; Vincent J Benn; Jay Zhang; Li Li; Min Zhang; Xiaojuan Tan; Qingmei Liu; Robert K Flamm Journal: Antimicrob Agents Chemother Date: 2020-04-21 Impact factor: 5.191
Authors: Ayesha Khan; William R Miller; Dierdre Axell-House; Jose M Munita; Cesar A Arias Journal: J Clin Microbiol Date: 2022-06-13 Impact factor: 11.677
Authors: Elizabeth A Lakota; Scott A Van Wart; Michael Trang; Evan Tzanis; Sujata M Bhavnani; M Courtney Safir; Lawrence Friedrich; Judith N Steenbergen; Paul G Ambrose; Christopher M Rubino Journal: Antimicrob Agents Chemother Date: 2020-06-23 Impact factor: 5.191